Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Oktober 2023 16:05 ET | Quelle: Immuneering Corporation

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
11. Oktober 2021 06:50 ET | Quelle: Immuneering Corporation

Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with...
01. Oktober 2021 06:50 ET | Quelle: Immuneering Corporation

Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition Company to Host Key Opinion Leader...